Acute myeloid leukemia 1 (AML1) gene on chromosome 21 is involved in several chromosomal translocations, including t(8;21) and t(16;21), that produce chimeric fusion proteins AML1-eight twenty-one (ETO) and AML-myeloid transforming gene chromosome 16 (MTG16), which contribute to leukemogenesis. The molecular basis for the leukemogenic effects of these fusion proteins is incompletely understood. Using gel-shift assay, we showed that AML1-ETO and AML1-MTG16 bound to a series of AML1 consensus DNA-binding sites with different affinities. Using fluorescence recovery after photobleaching (FRAP), we demonstrated that a fusion of AML1 with ETO or MTG16 exhibits reduced intranuclear mobility compared with wild-type AML1 or either fusion partner. The dimerization domain (nervy homology region 2) of ETO is responsible for the reduced mobility of AML1-ETO. Dual FRAP studies revealed that CBFb colocalized with AML1-ETO within the nucleus, resulting in reduced mobility of CBFb. Therefore, AML1 fusion proteins may interfere with normal AML1 function due to aberrant nuclear dynamics, which leads to spatial and temporal sequestration of CBFb and perhaps other coregulators critical for myeloid differentiation.
Introduction
The acute myeloid leukemia 1 (AML1, also called RUNX1) and CBFb genes are the most frequent targets involved in leukemia-associated chromosomal translocations (Lutterbach and Hiebert, 2000; Licht, 2001) . Understanding the molecular basis for the leukemogenic effects of these fusion proteins is an important but, as yet, unrealized goal in the field of leukemogenesis. The AML1 gene encodes a nuclear heterodimeric transcription factor (Lutterbach and Hiebert, 2000) ; it was identified in the early 1990s by cloning the t(8;21) chromosomal translocation morphologically associated with M2 subtype acute myeloid leukemia (AML) of the French-American-British (FAB) classification (Licht, 2001) . CBFb is a protein that does not itself bind DNA, rather dimerizes with AML1, thereby increasing its DNA-binding affinity. CBFb is involved in chromosomal inversion inv(16), which generates the CBFb-MYH11 fusion gene, in AML subtype M4 with eosinophilia (Adya et al., 1998) . The N-terminal runt homology DNA-binding domain (RHD) of AML1 mediates both AML1 heterodimerization with the CBFb protein and binding of AML1 to its consensus DNAbinding sequence, which is present in numerous myeloid/lymphoid promoters/enhancers, including GM-CSFR, M-CSFR, IL-3 and p14 ARF (Peterson and Zhang, 2004) . Several splice variants of AML1 have been detected, including an AML1 variant lacking the C-terminal transactivation domain, AML1A, and the largest AML1 isoform, AML1B (Meyers et al., 1995; Lutterbach and Hiebert, 2000) .
Translocation t(8;2 l), which generates a new hybrid gene called AML1-eight twenty-one (ETO), occurs in approximately 12-15% cases of AML. The ETO gene family consists of three members: ETO (also called MTG8), myeloid transforming gene-related protein-1 (MTGR1) and myeloid transforming gene chromosome 16 (MTG16) (Davis et al., 2003) . Myeloid transforming gene chromosome 16 is a putative breast tumor suppressor gene that is highly expressed in many human tissue types. The MTG16 gene encodes two alternative splice variants, MTG16a and MTG16b, which differ in their 5 0 regions. Translocation t(16;21) and t(3;21) generate AML1-containing chimeric genes in which the fusion partner of AML1, on chromosome 16 and chromosome 3, is the MTG16 gene and EVI1 gene, respectively. These rare chromosomal abnormalities have been found to occur in therapy-related leukemia and in chronic myelogenous leukemia (CML) in blast crisis (Gamou et al., 1998; Lutterbach and Hiebert, 2000) .
The application of the green fluorescent protein (GFP) with fluorescence recovery after photobleaching (FRAP) technique not only allows for direct visualization of protein localization within cells, but also has recently been used to address a number of biological questions regarding protein dynamics and interactions with other components using a real-time and live singlecell system (Misteli, 2001; Hinojos et al., 2005) . The studies of the intranuclear mobility of estrogen receptor (ER) revealed that ER and the coactivator SRC-1 moved rapidly through the nucleus in the absence of ligand and that their mobility decreased upon activation by ligand (Stenoien et al., 2001) . Using FRAP, we recently demonstrated that the intranuclear mobility of each of the five acute promyelocytic leukemia (APL) fusion proteins described was reduced compared to wild-type retinoic acid receptor a (RARa). Furthermore, coexpression of the most commonly occurring APL fusion protein, PML-RARa, with RXRa within live cells resulted in mislocalization and reduced mobility of RXRa .
To gain spatiotemporal insight into how AML1-X (X:ETO, MTG16, EVI1) may interfere with normal AML1 function, we employed FRAP of fluorescent protein-tagged AML1, AML1-X and X. Our findings demonstrated that the intranuclear mobility of each AML1-X was reduced compared to both normal AML1 and component X, and that the dimerization domain (nervy homology region (NHR2) of ETO plays an important role in the reduction of AML1-ETO mobility. Furthermore, we demonstrated that AML1-ETO colocalized with CBFb and led to a marked reduction of CBFb intranuclear mobility. Thus, part of the leukemogenic effect of AML1-X may be mediated by its ability to spatially and temporally sequester coregulators critical for myeloid differentiation.
Results

AML1
-eight twenty-one and AML1-myeloid transforming gene chromosome 16 bind to a series of AML1 consensus binding sites It has been suggested that AML1-ETO fusion proteins contribute to leukemogenesis by binding to AML1 consensus sequences, thereby repressing gene transcription essential for myeloid differentiation (Meyers et al., 1995; Licht, 2001) . To determine if AML1-ETO is capable of binding to a series of AML1 consensus sequences and to compare its binding to that of AML1-MTG16, we expressed AML1-ETO and AML1-MTG16 proteins in 293T cells and examined each protein by gel-shift assay using a series of AML1 DNAbinding sequences identified within the enhancer/promoter regions of human genes, including RUNX3 (AML2), BCL-2, TCRa, CD11a/CD18 (leukocyte function-associated antigen 1, LFA-1) and M-CSFR (Peterson and Zhang, 2004) . As shown in Figure 1a , AML1-ETO and AML1-MTG16 can bind to each of the AML1 consensus sequences tested; binding could be competitively inhibited by 100-fold excess of unlabelled probe (data not shown). Each gel-shift band was supershifted with antisera to AML1, ETO or MTG16 (ETO-2), demonstrating that each was composed of AML1, AML1-ETO or AML1-MTG16 protein, respectively, bound to DNA (Figure 1b) . Overall, the AML1-ETO binding preferences were similar to AML1-MTG16, although AML1-MTG16 bound to each sequence less efficiently than AML1-ETO (Figure 1a) .
It is important to know whether AML1-ETO and AML1-MTG16 also bind to AML1-binding sequences in vivo. To this end, we expressed hemagglutinin (HA)-tagged AML1-ETO and AML1-MTG16 in Xenopus oocytes by injection of their in vitro synthesized mRNA into the cytoplasm (Figure 1c ) or in mammalian 293 T cells by transient transfection assay (Figure 1d) . A RUNX3-Luc reporter construct containing one copy of the AML1 consensus DNA-binding site was integrated into chromatin via replication-coupled chromatin assembly following injection of its double-stranded DNA into the nuclei of oocytes . Molecular interactions in vivo between AML1-ETO or AML1-MTG16 and the RUNX3 promoter AML1-binding site in oocytes or 293T cells was investigated by chromatin immunoprecipitation (ChIP) assay (Yoon et al., 2003) . PCR amplification of input genomic DNA and of anti-HA or anti-AML1 immunoprecipitants from both oocytes and 293T cells gave PCR products of the expected size (150 bp; Figure 1c and d). These data indicate that AML1-ETO and AML1-MTG16 interact with the AML1-binding site within the RUNX3 promoter/enhancer in vivo as well as in vitro (Figure 1a ).
Nervy homology region 2 domain is responsible for the formation of acute myeloid leukemia 1-eight twenty-one homodimer detected by gel-shift assays It is well known that ETO protein is composed of four evolutionarily conserved NHR domains (Minucci et al., 2000; Zhang et al., 2001; Davis et al., 2003) . The NHR2 domain is the dimerization domain, which plays an important role in homodimerization and heterodimerization between the ETO family members as well as ETO and AML1-ETO. Nervy homology region 4 contains two zinc-finger motifs, which are involved in protein-protein interactions with transcriptional corepressors such as SMRT and N-CoR. This interaction requires both the presence of the NHR4 and the adjacent sequence of NHR3. We and others have demonstrated that the dimerization domain of APL fusion proteins, including PML-RARa, PLZF-RARa, STAT5b-RARa and NuMA-RARa (Dong and Tweardy, 2002; Dong et al., 2003; So and Cleary, 2004) , is important for DNA/APL fusion protein complex formation and oncogenic activities. To investigate whether or not the ETO dimerization domain (NHR2) contributes to AML1-ETO protein/DNA complex formation, we constructed two AML1-ETO mutants, AML1-ETO(DNHR2) and AML1-ETO(DNHR34), in which the NHR2 domain and NHR3 to NHR4 from ETO were deleted, respectively. As shown in Figure 1e , AML1-ETO(DNHR2) and AML1-ETO(DNHR34) bound as efficiently to the AML1-binding sites as the full-length AML1-ETO, indicating that the NHR2 domain as well as the NHR3-to-NHR4 domain are not critical for DNA-binding of AML1-ETO. However, we observed that the AML1-ETO(DNHR2)/DNA complex moved much faster than that of the AML1-ETO(DNHR34) (Figure 1e, upper panel) . As the molecular mass of AML1-ETO(DNHR2) is greater than that of AML1-ETO(DNHR34) (Figure 1e , bottom panel), these results suggest that while AML1-ETO and AML-ETO(DNHR34) bind the AML1 consensus P-labeled RUNX3 probe (1 ng) was incubated with 20 mg of WCE from 293T cells transfected with empty vector pSG5 (lanes 1 and 2), AML1B (lanes 3 and 4), AML1-ETO (lanes 5-7), AML1-MTG16(II) (lanes 8-10) and AML1-MTG16(I) (lanes 11-13). Antibody against AML1, ETO or MTG16 (ETO-2) serum was added to the reactions where indicated. (c) Both AML1-ETO and AML1-MTG16 bind to AML1 consensus sequence from human RUNX3 enhancer/promoter region using Xenopus oocyte microinjection system and the subsequent ChIP assays with HA antibody (lanes 4-6) or AML1 antibody (lanes 7-9). The proteins from the oocytes injected with mRNA for AML1-ETO and AML1-MTG16 were determined by Western blot with antibody against HA-tagged or AML1 (bottom panel). (d) Extracts of 293T cells following transient transfection with HA-AML1-ETO (in pSG5) (lanes 1 and 4, left panel), HA-AML1-MTG16(II) (in pSG5) (lanes 2 and 5, left panel) or empty pSG5 vector (lanes 3 and 6, left panel) were subjected to ChIP assay using HA antibody (lanes 4-6, left panel) (Yoon et al., 2003) . The protein expression levels of 293T cells transfected by HA-AML1-ETO (lane 1, right panel), HA-AML1-MTG16(II) (lane 2, right panel) or empty vector (lane 3, right panel) was determined by immunoblotting with mouse anti-HA antibody. (e) Green fluorescent protein-untagged or tagged AML1-ETOs in which the NHR2 domain (AML1-ETO(DNHR2)) (lanes 2, 4, 7, and 9) or the NHR3-NHR4 domain (AML1-ETO(DNHR34)) (lanes 3, 5, 8, and 10) is deleted demonstrates binding to RUNX3 probes equivalent to full-length AML1-ETO, and is supershifted by antibodies against AML1. The level of protein expression, determined by immunoblotting with antibody against the N-terminal of AML1, is shown in the bottom panel.
Western Blot
Nuclear dynamics of AML1 fusion proteins J Qiu et al sequence as a dimer, AML1-ETO(DNHR2) most likely binds to this element as a monomer, in agreement with the NHR2 domain of ETO being responsible for the formation of AML1-ETO homodimer (Minucci et al., 2000; Zhang et al., 2001; Davis et al., 2003) .
Characterization of green fluorescent protein-tagged wildtype AML1, AML1-X and X To study the intracellular mobility of wild-type AML1 and AML1-X in living cells, we created constructs expressing GFP chimeras fused to the N-terminal ends of AML1 or AML1-X as well as its normal X component. Immunoblot analysis of whole-cell extracts (WCE) from transfected cells showed that each of the GFP-tagged constructs encoded proteins of the correct size ( Figure 2a and data not shown). The attachment of GFP rarely affects the function and localization of the fusion protein (Stenoien et al., 2000; Dong et al., 2004) .
In fact, addition of GFP to AML1 and AML3 did not change their ability to transactivate by transcription assays (Harrington et al., 2002) . To be certain that the tagging of GFP to AML1 or AML1-X did not significantly alter the functional characteristics of AML1 or AML1-X, we evaluated the DNA-binding activity of GFP-AML1 or GFP-AML1-X using gelshift assays with the RUNX3 DNA-binding element. This element is an AML1-binding sequence located within the human RUNX3 promoter/enhancer region (Bangsow et al., 2001) . Gel-shift assays demonstrated that GFP-AML1 and GFP-AML1-X bound as efficiently to this AML1 sequence as their untagged counterpart, indicating that the addition of GFP did not change the DNA-binding properties of AML1 and AML1-X ( Figure 2b ). Similarly, we found that addition of GFP did not affect DNA-binding by AML1-ETO mutants, AML1-ETO(DNHR2) and AML1-ETO(DNHR34) (Figure 1d ).
Cellular localization of green fluorescent protein-tagged acute myeloid leukemia 1-related proteins
We examined the intracellular distribution of GFP-AML1, GFP-AML1-X and its normal GFP-X counterpart, as well as GFP-CBFb and GFP-CBFb-MYH11, and found that these proteins localized mostly within the nucleus (Figure 3 ), similar to previous immunofluorescence microscopy observations for wildtype AML1, AML1-X and normal X partners (Adya et al., 1998; Tanaka et al., 1998; Barseguian et al., 2002) . Of interest, AML1A and AML1B show distinct intranuclear localization patterns, with GFP-AML1A having a diffuse pattern within the nucleus while GFP-AML1B has a microspeckled distribution. Green fluorescent protein-tagged AML1-ETO, ETO, AML1-MTG16(I), AML1-MTG16(II), MTG16a, MTG16b, MTGR1, AML1-EVI1 and EVI1 also each displayed a microspeckled pattern superimposed upon a diffuse distribution. Interestingly, AML1-ETO with deletion of the NHR2 domain or NHR3-to-NHR4 domains also showed a similar microspeckled pattern within the nucleus, suggesting that the deletion of NHR2 dimerization domain or the NHR3-to-NHR4 domains of AML1-ETO may not affect the cellular localization of AML1-ETO. Green fluorescent protein-CBFb is distributed diffusely within both the cytoplasm and nucleus, while GFP-CBFb-MYH11 is located predominantly within the nucleus with a diffuse distribution and sparsely within the cytoplasm, demonstrating that the CBFb fusion protein has an aberrant subcellular distribution, as reported previously (Adya et al., 1998) . Cotransfection of CFP-AML1-ETO and YFPCBFb in HeLa cells demonstrated that these two proteins colocalized within the nucleus in microspeckles (Figure 6a ). These results indicate that CBFb binds to AML1-ETO and localizes within the nucleus in a distribution pattern characteristic of AML1-ETO.
The mobility of AML1-X is decreased compared to wildtype AML1 and X To study the intranuclear mobility of AML1, AML1-X and X, we transfected GFP-tagged constructs and performed FRAP analysis ( Figure 4 and Table 1 ) by using live HeLa cell lines that lack endogenous RUNX factors (Zaidi et al., 2002) . A rectangular region within the nucleus was bleached by applying maximal laser power for approximately 1 s (Stenoien et al., 2001; Dong et al., 2004) . In all FRAP experiments, only cells expressing low levels of protein were examined to avoid artifacts of overexpression, as we described previously (Stenoien et al., 2001; Dong et al., 2004) . Figure 4 shows images taken right before bleaching (pre-bleach), immediately after bleaching (bleach) and at several time points after bleaching. Following photo-bleaching of live HeLa cells transfected with GFP-AML1A, fluorescence recovery occurred rapidly with a half-maximal fluorescence recovery time (t 1/2 ) of 0.8570.15 s (Table 1) . In comparison with AML1A, which is the short form of AML1, AML1B, the longer form of AML1, had reduced mobility (t 1/2 of 2.9170.50 s, Po0.001). This is perhaps expected since AML1B, but not AML1A, contains the nuclear matrix-targeting signal (NMTS) sequence within its C-terminus. Role of the nervy homology region 2 dimerization domain in the decreased intranuclear mobility of acute myeloid leukemia 1-eight twenty-one We recently reported that, in addition to being essential for other oncogenic functions, the coiled-coil dimeriza-tion domain of NuMA in NuMA-RARa was responsible for the reduced mobility of CFP-NuMA-RARa compared to CFP-RARa and its slowing in response to ligand . In this study, we next examined whether or not the dimerization domain (NHR2 domain) or the NHR3-to-NHR4 portion of AML1-ETO contributes to its mobility reduction within the nucleus. The AML1-ETO mutants, in which the dimerization domain (NHR2) or NHR3-to-NHR4 portion has been deleted, were created. Following transient transfection into HeLa cells, we found that their intranuclear localization was similar to AML1-ETO and demonstrated a microspeckled distribution (Figure 3 ). To study if the dimerization domain (NHR2)
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Ab-GFP Gel-shift assay analysis of the in vivo expressed untagged or GFP-tagged AML1 and AML1-X proteins using the probe from the enhancer/promoter sequence of human RUNX3 gene.
Nuclear dynamics of AML1 fusion proteins J Qiu et al or the NHR3-to-NHR4 portion of AML1-ETO is responsible for the reduced mobility of AML1-ETO, FRAP analysis was performed on the two mutants, GFP-AML1-ETO(DNHR2) and GFP-AML1-ETO (DNHR34) (Figure 4 and Figure 5a ). GFP-AML1-ETO(DNHR2) demonstrated rapid intranuclear mobi- Figure 5a and Table 1 ). In contrast, the mobility of GFP-AML1-ETO(DNHR34) was very close to AML1-ETO (P ¼ 0.34). Therefore, similar to its contribution to other oncogenic activities of AML1-ETO (Minucci et al., 2000; Zhang et al., 2001) , the NHR2 dimerization also plays a key role in the mobility reduction of AML1-ETO.
Effect of acute myeloid leukemia 1-eight twenty-one on intranuclear localization and mobility of CBFb In vitro, both AML1 and AML1-ETO are required to form a heterodimeric complex with CBFb to bind with high affinity to AML1 consensus DNA-binding sequences (Licht, 2001) . To determine if AML1-ETO alters not only the intranuclear localization of CBFb but also its intranuclear mobility, we performed dual-FRAP analysis of live HeLa cells transfected with CFP-AML1-ETO and YFP-CBFb (Figure 6 ). YFP-CBFb alone distributed within the cytoplasm and nucleus in a diffuse pattern (Figure 6a ) and had very fast intranuclear mobility with a recovery t 1/2 ¼ 0.5070.10 s, which is even faster than AML1A (Figure 6b ). Cotransfection of cells with YFP-CBFb and CFP-AML1-ETO not only resulted in the change in nuclear distribution of CBFb, in which YFP-CBFb colocalized with CFP-AML1-ETO in a intranuclear microspeckled pattern (Figure 6a ), but also reduced the intranuclear mobility of CBFb by 18-fold (recovery t 1/2 ¼ 9.1472.91 s; Po0.001; Figure 6c and d).
Discussion
In the present study, we evaluated the distribution and intranuclear mobility of AML1-X fusion proteins, along with AML1 and X, in fixed and live cells to gain new insights into the leukemogenic mechanisms of this important group of oncogenic chimeric proteins identified with greatest frequency in AML. Our real-time single-cell studies revealed for the first time that each of 
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Reduced intranuclear mobility of leukemia-related fusion proteins resulting from chromosomal translocation has been reported in APL . Acute promyelocytic leukemia chimeric proteins (X-RARa) contain RARa fused at the N-terminal end with one of five partner proteins (X: PML, PLZF, NPM, NuMA, STAT5b). Each APL fusion protein demonstrated reduction of intranuclear mobility compared with wild-type RARa, which was accompanied by its altered distribution within the nucleus consisting of a microspeckled pattern rather than a diffuse distribution characteristic of RARa. This raised the possibility that the altered mobility was a reflection of the altered intranuclear address of each of the proteins . While there are similarities in nuclear localization and intranuclear mobility between AML1-X and XRARa that suggest the possibility of a common and perhaps general mechanism of action of oncogenic transcription factor-containing fusion proteins, it is important to note that there are differences in the magnitude of the reduction in mobility between AML1-and RARa-related oncogenic fusion proteins, as well as in how the mobility of the fusion protein compares with its two wild-type counterparts. The degree of mobility reduction for AML1-X is 4.2-14.5-fold compared to AML1A and 1.23-4.2-fold compared to AML1B, respectively, while APL fusion proteins were reduced only 1.7-3.9-fold and 1.8-4.7-fold compared to wildtype RARa, in the absence or presence of retinoic acid, respectively. In addition, each AML1-X protein is slower than both wild-type AML1 and its X counterpart, while each APL fusion protein, except for STAT5b-RARa, is slower than wild-type RARa but faster than its normal X counterpart. This suggests the possibility that the molecular basis for the reduced mobility of AML1-X may be distinct from that for X-RARa.
Compartmentalization of the transcriptional regulatory machinery into discrete, yet highly dynamic, subnuclear foci may be critical for the accurate control of gene expression through as yet ill-defined mechanisms. These functional subnuclear foci may serve to briefly concentrate gene regulatory factors including gene-specific transcription factors and coregulators, but the active form of RNA pol II is rarely at these transient sites. Recent photobleaching experiments suggest that these regulatory proteins diffuse through the nuclear space and transiently accumulate in a steady-state compartment by interaction with local high-affinity binding sites, such as chromatin territory or transcriptional sites (Misteli, 2001) , or may simply be the result of stochastic interactions between various binding partners irrespective of gene regulatory units. It was observed that a small portion of AML1 proteins localized to subnuclear sites of active transcription (Harrington et al., 2002) . In the case of steroid receptors, there is a correlation between their spatial reorganization and transcriptional competence; however, the functional significance of these foci formation remains unclear (Stenoien et al., 2000) . We showed here that AML1-X and AML1 can bind to a series of AML1 consensus DNA-binding sites with fast mobility (t 1/2 from 0.85 to 12.30 s) within the nucleus, reflecting the transcription factors AML1-X or wild-type AML1 dynamically interact with stationary subnuclear foci. It has been suggested that t(8;21) translocation results in rearrangement of the normal targeting signals of AML1, which misroutes the fusion protein away from AML1 foci to an ETO intranuclear address (McNeil et al., 1999) . Our FRAP analysis demonstrated that the nuclear mobility of AML1-ETO is distinct from ETO, suggesting that either the intranuclear address for AML1-ETO is distinct from ETO or that the AML1-ETO dynamically binds with greater affinity to the ETO address. It was reported that during cellular differentiation, changes in transcriptional activity are often coupled to alterations in nuclear location (Francastel et al., 2001) . Our FRAP data also showed distinct intranuclear mobility between AML1-X and AML1, although AML1-X and AML1 can bind the same DNA-binding sites in vitro. It is hard to speculate from our FRAP data whether this phenomenon is the reflection of localization by AML1-X and AML1 to different nuclear foci, or different binding within the same nuclear foci or chromatin sites. Solutions to this question will likely require the use of single-cell analyses and AML1 integrated promoters that allow live readout of transcription (Hinojos et al., 2005) .
The hypothesis that activation of oncogenic properties of proto-oncogenic proteins occurs through homodimerization has been proposed in hematopoietic malignancies (So and Cleary, 2004) . The NHR2 domain, which mediates homodimerization and heterodimerization of ETO family proteins, may itself be sufficient for the oncogenic activity of AML1-ETO (Minucci et al., 2000) and is important for the association of ETO with several proteins (Davis et al., 2003; Peterson and Zhang, 2004) . It was reported that removal of the NHR2 domain diminished the ability of AML1-ETO to block hematopoietic differentiation of U937 cells (Zhang et al., 2001; Hug et al., 2002) . Sin3 is directly dependent on this domain for interactions with ETO, whereas corepressors for nuclear hormone receptor, SMRT and NCoR, are indirectly dependent on this domain to facilitate interactions with the NHR4 domain of ETO (Zhang et al., 2001) . In the studies reported here, we demonstrated that the NHR2 domain of ETO was responsible for the reduction of intranuclear mobility of AML1-ETO, which is reminiscent of that for NuMARARa, in which the coiled-coil domain of NuMA was found to be responsible for the mobility reduction of NuMA-RARa . This result suggests either that the NRH2 is directly responsible for the reduced mobility or that removal of the NRH2 domain from AML1-ETO alters the structure elsewhere within the fusion protein, leading to its increased mobility. Identifying the proteins that interact with the NHR2 domain will no doubt improve our understanding of the mechanisms of AML1-ETO-mediated leukemogenesis. The POZ domain, which mediates the homodimer formation of PLZF-RARa, is the minimal transformation domain for PLZF-RARa-mediated transformation of primary hematopoietic cells (So et al., personal communication) . Therefore, it will be very important to determine whether or not the NHR2 domain is responsible for AML1-ETO's transformation ability. This information might provide the molecular basis for novel therapeutic approaches in leukemia.
The RHD domain of AML1 interacts with many coregulatory factors (e.g., CBFb and C/EBP) to regulate gene expression (Peterson and Zhang, 2004) . In our present work, CBFb and AML1-ETO were shown to dynamically colocalize within subnuclear foci. Furthermore, when AML1-ETO and CBFb are coexpressed, the mobility of CBFb is reduced 18-fold compared to its mobility when expressed alone. Thus, in addition to altering the nuclear distribution of CBFb, AML1-ETO leads to markedly reduced mobility of CBFb proteins. This is reminiscent of our findings in PML-RARa in which RXRa aberrantly colocalized with each PMLRARa into microspeckles; colocalization of RXRa with PML-RARa was accompanied by its reduced mobility . Three highly conserved AML genes have been identified: AML1 (RUNX1), AML2 (RUNX3) and AML3 (RUNX2), each of which needs CBFb as a cofactor to precisely regulate gene expression. Therefore, the compartmentalization and reduced mobility of CBFb by AML1-ETO may interfere with its normal functions, including the formation of heterodimers with AML1-3 (Lutterbach and Hiebert, 2000) . The result may be alterations in gene expression regulated by AML1-3, contributing to the development of acute myeloid leukemia (Westendorf and Hiebert, 1999) . In addition to binding and compartmentalizing CBFb, our findings raise the possibility that AML1-ETO may also dynamically compartmentalize other coregulators into subnuclear foci, either through the AML1 RHD domain, such as C/EBP family, ETS family, GATA-1, Smad3 (Peterson and Zhang, 2004) , or through the ETO moiety, such as SMRT, NCoR, HDAC1, HDAC3, PLZF, BCL6 (Davis et al., 2003) , leading to alteration of genes transcriptional by regulated by this important class of transcriptional regulators. Therefore, alterations in the intranuclear mobilities of CBFb or other coregulators, interacting with the moiety of AML1 or ETO, may form the molecular basis for the pathogenesis of leukemia simply by altering the probabilistic chance of functionally relevant interactions at genomic sites of transcriptional regulation. Lending support to the hypothesis that the altered compartmentalization of nuclear coregulators can have an important impact on cell fate is the finding that compartmentalization of the tumor-suppressor ARF protein in the nucleolus plays a pivotal role in growth arrest (Korgaonkar et al., 2002) .
Taken together with the findings reported herein regarding the reduced mobility of AML1-X and its ability to be colocalized with CBFb and thereby alter its distribution and mobility, these results raise the possibility that the site of the leukemogenic effects of AML1-X oncogenic fusion proteins may extend beyond the promoters of genes bound by the fusion protein to the site of compartmentalization of the fusion protein.
in ice-cold lysis buffer (20 mM HEPES, pH 7.9, 420 mM NaCl, 20 mM NaF, 1 mM Na 3 VO 4 , 1 mM Na 4 P 2 O 7 , 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 20% glycerol, 0.5 mM PMSF) as reported previously (Dong and Tweardy, 2002) . Equivalent amounts of protein were electrophoresed on 7.5 or 10% SDS polyacrylamide gels and transferred to PVDF membrane (Millipore). Proteins were detected by using antibodies: AML1 goat polyclonal antibody (N-20), ETO goat polyclonal antibody (C-20), ETO-2 (MTG16) goat polyclonal antibody (C-20) (Santa Cruz Biotech.) and GFP rabbit polyclonal antibody . Immunoreactive bands were visualized using the enhanced chemiluminescence kit (Amersham Biosciences Corp.).
Gel-shift DNA-binding assays The untagged and/or GFP-tagged AML1A, AML1B, AML1-MTG16(I), AML1-MTG16(II), AML1-ETO, AML1-ETO(DNHR2) and AML1-ETO(DNHR34) proteins were expressed in 293T cells. Gel-shift assays were performed as described previously (Dong and Tweardy, 2002) using 20 mg of WCE of 293T cells transfected with the indicated constructs. Briefly, extracts were preincubated for 10 min at room temperature in 20 ml of reaction buffer, which contains 20 mM HEPES, pH 7.9, 0.5 mM EDTA, 2 mM DTT, 10% glycerol, 50 mM KCl and 1 mg of poly (dI-dC) (Sigma). Supershift experiments were performed using 1 mg of antibody against the N-terminal of AML1 or C-terminal of ETO or MTG16 (ETO-2). 32 P-labeled duplex oligonucleotide probe for AML1 consensus DNA-binding sequence was added. Protein/ DNA complexes were separated on 5% polyacrylamide gels equilibrated in 0.25 Â TBE. Gels were dried and analysed on a PhosphorImager (Molecular Dynamics) with the ImageQuant software.
In vitro mRNA synthesis, microinjection of Xenopus oocytes and chromatin immunoprecipitation assay Preparation and microinjection of mRNAs (AML1-ETO and AML1-MTG16) and reporter DNA (RUNX3-luc-reporter) into stage VI Xenopus oocytes was performed as described previously . Both AML1-ETO and AML1-MTG16 (in pSP64(polyA), Promega) vectors for in vitro transcription experiment were linearized with AflII restriction enzyme and the SP6 mMessage mMachine kit (Ambion) was applied for the in vitro mRNA synthesis according to the manufacturer's instruction. The injected Xenopus oocytes or the mammalian 293T cells following transient expression of HA-AML1-ETO and HA-AML1-MTG16 proteins were processed for ChIP analysis as described (Yoon et al., 2003; Stewart et al., 2005) using primers located in the proximal region of AML1 consensus sequence of human RUNX3 gene. The extract from oocytes or 293T cells was sonicated in a cold room to break chromatin into fragments averaging 500 bp in length (Yoon et al., 2003; Stewart et al., 2005) and subsequently used for ChIP experiment with a specific mouse monoclonal HA-tagged (6E2) antibody (Cell Signaling) and/or rabbit polyclonal AML1(Ab-1) antibody (Oncogene). The final PCR reactions were performed with inclusion of [a-32 P]dATP; the PCR products were visualized by autoradiography following fractionation on a 6% native polyacrylamide gel.
Fluorescence microscopy and fluorescence recovery after photo-bleaching For fixed cell experiments, HeLa cells were plated onto poly-Dlysine-coated coverslips in 24-wells plate, cultured in Opti-MEM I media (Invitrogen) with 4% FBS (Invitrogen) and transfected with 200 ng of GFP-tagged constructs using GeneJuice transfection reagent (Novegen) as described . After 48 h transfection, cells were processed for fluorescence microscopy by fixation in 4% formaldehyde in PEM buffer (80 mM PIPES, pH 6.8, 5 mM EGTA, 2 mM MgCl 2 ) for 30 min at 41C. Subsequently, these transfected HeLa cells were quenched in 1 mg/ml of NaBH 4 (Sigma) in PEM buffer, counterstained for 1 min in 4,6-diamidino-2-phenylindole (DAPI) (Sigma) (1 mg/ml, in PEM buffer) and mounted in Slow Fade reagent (Molecular Probes). Deconvolution microscopy was performed on a Zeiss Axiovert S100 TV microscope and a DeltaVision Restoration Microscopy System (Applied Precision) as described previously (Stenoien et al., 2000) . We (Stenoien et al., 2001; Dong et al., 2004) have extensively described FRAP analysis of the mobility of fluorescence-tagged proteins within the nucleus. Briefly, for photo-bleaching studies, 24 h before transfection, cells were plated onto 40-mm coverslips in 60-mm dish at a concentration of 2 Â 10 5 cells per dish. Transient expression of plasmids, GFP-tagged, CFP-tagged or YFP-tagged, was accomplished using GeneJuice transfection reagent (Novegen) as described . The subsequent FRAP experiments were performed on Zeiss LSM 510 confocal microscopes using the laser set at a wavelength of 488 nm for GFP or a wavelength of 458 nm for CFP at a maximum power for 75 or 100 iterations of a box representing B20% of the nuclear volume. For dual FRAP experiments, both were bleached with the same laser setting at 458 nm and simultaneous images corresponding to the CFP and YFP fluorescence were obtained using the multitracking function of the microscope (Stenoien et al., 2001; Dong et al., 2004) . A minimum of 10 cells were examined at each conditions. Fluorescence intensities of regions of interest (ROI) were obtained using LSM510 software, and data were exported to Excel (Microsoft) for analysis.
